Jazz Pharmaceuticals plc (JAZZ) Income Statement
JAZZ 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsJAZZ revenue and net income
Where JAZZ's revenue goes
2025Each bar shows an amount and its share of revenue. JAZZ kept −8.3% of revenue as net income.
JAZZ profit margins
JAZZ growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +4.9% | +5.3% | +12.5% | +12.4% |
| Gross profit | +3.9% | +6.5% | +11.2% | +11.9% |
| Operating income | −68.7% | — | −9.9% | −7.8% |
| Net income | −163.6% | — | — | — |
| EPS (diluted) | −66.7% | −18.7% | −10.8% | −2.9% |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
JAZZ quarterly EPS vs estimates
Jazz Pharmaceuticals beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 4, 2026 (estimate $5.66).
JAZZ income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B | $2.36B | $2.16B | $1.89B | $1.62B | $1.49B |
| Cost of revenue | $503.3M | $445.7M | $435.6M | $540.5M | $440.8M | $148.9M | $127.9M | $121.5M | $110.2M | $105.4M |
| Gross profit | $3.76B | $3.62B | $3.40B | $3.12B | $2.65B | $2.21B | $2.03B | $1.77B | $1.51B | $1.38B |
| Research & development | $782.7M | $884.0M | $849.7M | $590.5M | $505.7M | $335.4M | $299.7M | $226.6M | $198.4M | $162.3M |
| Sales, general & admin | $1.81B | $1.39B | $1.33B | $1.42B | $1.45B | $854.2M | $736.9M | $683.5M | $544.1M | $501.4M |
| Total operating expenses | $3.54B | $2.91B | $2.82B | $3.18B | $2.48B | $1.84B | $1.50B | $1.15B | $979.7M | $790.9M |
| Operating income | $224.4M | $716.6M | $578.6M | −$65.5M | $170.3M | $378.1M | $532.4M | $614.8M | $528.8M | $591.7M |
| Interest income | — | — | — | — | — | — | $82.2M | $86.2M | $88.7M | $58.9M |
| Interest expense | $195.1M | $238.1M | $289.4M | $288.2M | $278.8M | $99.7M | $72.3M | $78.5M | $77.8M | $61.9M |
| Income before taxes | −$628.6M | $468.7M | $294.9M | −$382.7M | −$113.6M | $272.1M | $450.2M | $527.3M | $440.1M | $532.1M |
| Income taxes | −$272.4M | −$91.4M | −$119.9M | −$158.6M | $216.1M | $33.5M | −$73.2M | $80.2M | −$47.7M | $135.2M |
| Net income | −$356.1M | $560.1M | $414.8M | −$224.1M | −$329.0M | $238.6M | $523.4M | $447.1M | $487.8M | $396.8M |
| EBITDA | $262.8M | $1.52B | $1.45B | $1.47B | $1.03B | $1.04B | $1.01B | $932.7M | $779.0M | $753.9M |
| EPS (diluted) | $7.06 | $21.19 | $18.32 | $13.13 | $16.23 | $12.47 | $16.24 | $13.69 | $11.04 | $10.17 |
| Gross margin | 88.2% | 89.0% | 88.6% | 85.2% | 85.8% | 93.7% | 94.1% | 93.6% | 93.2% | 92.9% |
| Operating margin | 5.3% | 17.6% | 15.1% | −1.8% | 5.5% | 16.0% | 24.6% | 32.5% | 32.7% | 39.8% |
| Net margin | −8.3% | 13.8% | 10.8% | −6.1% | −10.6% | 10.1% | 24.2% | 23.6% | 30.1% | 26.7% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.21B | $1.07B | $1.20B | $1.13B | $1.05B | $897.8M | $1.09B | $1.05B | $1.02B | $902.0M | $1.01B | $972.1M |
| Cost of revenue | $116.4M | $306.4M | $24.6M | $257.8M | $116.3M | $104.6M | $128.7M | $111.6M | $109.9M | $95.5M | $258.8M | $102.2M |
| Gross profit | $1.09B | $762.5M | $1.17B | $868.3M | $929.4M | $793.2M | $959.5M | $943.4M | $913.9M | $806.5M | $753.1M | $870.0M |
| Research & development | $207.5M | $134.1M | $171.4M | $240.7M | $190.0M | $180.7M | $240.5M | $199.9M | $220.7M | $222.8M | $216.6M | $234.4M |
| Sales, general & admin | $389.2M | $352.7M | $406.2M | $530.6M | $358.4M | $514.0M | $369.3M | $325.8M | $338.5M | $351.7M | $396.0M | $308.3M |
| Total operating expenses | $843.7M | $548.7M | $264.1M | $810.8M | $1.62B | $849.1M | $768.7M | $683.1M | $714.5M | $740.3M | $550.9M | $697.6M |
| Operating income | $248.2M | $213.8M | $909.2M | $57.5M | −$686.4M | −$55.9M | $190.8M | $260.2M | $199.4M | $66.2M | $202.2M | $172.4M |
| Interest expense | $37.1M | $63.3M | $45.4M | $48.6M | $47.4M | $53.7M | $51.3M | $58.7M | $62.0M | $66.1M | $89.7M | $71.5M |
| Income before taxes | $211.0M | $299.2M | $208.3M | $9.0M | −$735.6M | −$110.4M | $133.2M | $200.5M | $137.9M | −$2.9M | $61.5M | $99.6M |
| Income taxes | $18.1M | $6.1M | $4.9M | −$242.4M | −$17.1M | −$17.8M | −$57.9M | −$14.5M | −$30.7M | $11.7M | −$33.1M | −$47.2M |
| Net income | $192.8M | $293.1M | $203.5M | $251.4M | −$718.5M | −$92.5M | $191.1M | $215.1M | $168.6M | −$14.6M | $94.2M | $146.8M |
| EBITDA | $427.2M | $543.9M | $432.9M | $235.9M | −$514.2M | $138.9M | $397.0M | $424.5M | $363.0M | $268.5M | $361.4M | $333.7M |
| EPS (diluted) | $4.89 | $6.34 | $6.64 | $6.99 | −$8.25 | $1.68 | $6.60 | $6.61 | $5.30 | $2.68 | $5.02 | $4.84 |
| Gross margin | 90.4% | 71.3% | 97.9% | 77.1% | 88.9% | 88.3% | 88.2% | 89.4% | 89.3% | 89.4% | 74.4% | 89.5% |
| Operating margin | 20.5% | 20.0% | 75.9% | 5.1% | −65.6% | −6.2% | 17.5% | 24.7% | 19.5% | 7.3% | 20.0% | 17.7% |
| Net margin | 16.0% | 27.4% | 17.0% | 22.3% | −68.7% | −10.3% | 17.6% | 20.4% | 16.5% | −1.6% | 9.3% | 15.1% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in JAZZ's financial statements (latest annual report filed February 24, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
JAZZ financial results
In fiscal year 2025 (ended December 31, 2025), Jazz Pharmaceuticals reported revenue of $4.3 billion, up 4.9% from the year before. It had a net loss of $356.1 million, a net profit margin of −8.3%. Diluted earnings per share came to $7.06. Over five years revenue grew at an average rate of 12.5% a year.
See the JAZZ stock overview for the latest quote and news, or the JAZZ chart for price history and technical indicators.
JAZZ income statement FAQ
What is Jazz Pharmaceuticals's annual revenue?
Jazz Pharmaceuticals reported total revenue of $4.3 billion for fiscal year 2025, which ended on December 31, 2025. That was up 4.9% from $4.1 billion the previous year.
Is Jazz Pharmaceuticals profitable?
No. Jazz Pharmaceuticals reported a net loss of $356.1 million in fiscal 2025, a net profit margin of −8.3%; its operating margin was 5.3%.
What is Jazz Pharmaceuticals's gross margin?
Jazz Pharmaceuticals's gross margin was 88.2% in fiscal 2025: for every $100 of revenue, Jazz Pharmaceuticals kept $88 after the direct cost of its products and services.
How much does Jazz Pharmaceuticals spend on research and development?
Jazz Pharmaceuticals spent $782.7 million on research and development in fiscal 2025, 18.3% of revenue.
How fast is Jazz Pharmaceuticals growing?
Revenue grew 12.5% a year on average over the last five fiscal years, from $2.4 billion to $4.3 billion.
What are Jazz Pharmaceuticals's earnings per share?
Jazz Pharmaceuticals earned $7.06 per diluted share in fiscal 2025, compared with $21.19 a year earlier.
When will Jazz Pharmaceuticals report its next earnings?
Jazz Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes.
When does Jazz Pharmaceuticals's fiscal year end?
Jazz Pharmaceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 24, 2026.